Literature DB >> 6094001

Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

W Ross, T Rowe, B Glisson, J Yalowich, L Liu.   

Abstract

Epipodophyllotoxins are an important new class of anticancer agents which include the compounds VM-26 (teniposide) and VP-16 (etoposide). The mechanism of action of these drugs appears to involve production of DNA single- and double-strand breaks by virtue of a temperature-sensitive interaction between drug and a heat-labile intranuclear component. We now report evidence indicating that type II topoisomerase is the likely intracellular target for the DNA strand-breaking effects of the epipodophyllotoxins. Both VM-26 and VP-16 stimulate site-specific DNA cleavage by a highly purified calf thymus type II topoisomerase. VM-26 is 5- to 10-fold more potent than VP-16 in this assay, a difference that is also seen when DNA strand breaks are assayed in isolated nuclei of mouse leukemia cells following drug exposure. Furthermore, a similar potency difference exists with respect to cytotoxicity. Equilibrium dialysis experiments using [3H]VP-16 indicate that the drug does not bind to DNA. Thus, we suggest that the epipodophyllotoxins exert their anti-cancer effects by "poisoning" type II topoisomerase without binding to DNA. In this regard, their actions may be analogous to those of nalidixic acid in bacteria.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094001

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

1.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

2.  Etoposide-induced DNA cleavage in human leukemia cells.

Authors:  C M Edwards; B S Glisson; C K King; S Smallwood-Kentro; W E Ross
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Topoisomerase-specific drug sensitivity in relation to cell cycle progression.

Authors:  K C Chow; W E Ross
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

4.  The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Biochemistry       Date:  2006-03-07       Impact factor: 3.162

5.  Modification of the 8 drugs in 1 day regimen: feasibility of substitution of other agents.

Authors:  K W Chan; C J Fryer; P Steinbok
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

6.  Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms.

Authors:  Heidrun Ellinger-Ziegelbauer; Jennifer M Fostel; Chinami Aruga; Daniel Bauer; Eric Boitier; Shibing Deng; Donna Dickinson; Anne-Celine Le Fevre; Albert J Fornace; Olivier Grenet; Yizhong Gu; Jean-Christophe Hoflack; Masako Shiiyama; Roger Smith; Ronald D Snyder; Catherine Spire; Gotaro Tanaka; Jiri Aubrecht
Journal:  Toxicol Sci       Date:  2009-05-22       Impact factor: 4.849

Review 7.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

8.  Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.

Authors:  W R Waud; S D Harrison; K S Gilbert; W R Laster; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  DNA damage response to the Mdm2 inhibitor nutlin-3.

Authors:  Rajeev Verma; Marc J Rigatti; Glenn S Belinsky; Cassandra A Godman; Charles Giardina
Journal:  Biochem Pharmacol       Date:  2010-02-15       Impact factor: 5.858

10.  Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines.

Authors:  H Morimoto; P Principe; J P Robin; C Broquet; J M Mencia-Huerta; P Braquet; B Bonavida
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.